Table 2 Abnormal liver enzyme levels in peripheral blood: a comparison of COVID-19, SARS, and MERS
From: COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms
Reference | Study country | Number of patients | Elevated serum level | ||
|---|---|---|---|---|---|
Abnormal ALT, no. (%) | Abnormal AST, no. (%) | Abnormal TBil, no. (%) | |||
COVID-19 | |||||
Wang et al.5 | China | 105 | 40 (38.1%) | 33 (31.4%) | 24 (22.9%) |
Guan et al.4 | China | 1099 | 158 (21.3%)a | 168 (22.2%)b | 76 (10.5%)c |
Yang et al.17 | China | 149 | 18 (12.1%) | 27 (18.1%) | 4 (2.7%) |
Fan et al.58 | China | 148 | 27 (18.2%) | 32 (21.6%) | 9 (6.1%) |
Chen et al.59 | China | 99 | 28 (28.3%) | 35 (35.4%) | 18 (18.2%) |
Zhang et al.60 | China | 82 | 22 (30.6%)d | 44 (61.1%)d | 22 (30.6%)d |
Huang et al.61 | China | 36 | 4 (13%) | 18 (58.1%) | 4 (12.9%) |
Richardson et al.57 | USA | 5700 | 2176 (39.0%) | 3263 (58.4%) | NA |
Wu et al.62 | China | 157 | 12 (7.6%) | 25 (16.9%) | NA |
SARS | |||||
Cui et al.63 | China | 182 | 128 (70.3%) | 57 (31.3%) | NA |
Duan et al.64 | China | 154 | 41 (26.6%) | 4 (2.6%) | 13 (8.4%) |
Zhang et al.65 | China | 128 | 54 (42.2%) | NA | 17 (13.3%) |
MERS | |||||
Yousefi et al.66 | Iran | 5 | 2 (40%) | 3 (60%) | NA |
Assiri et al.67 | Saudi Arabia | 47 | 5 (11.0%) | 7 (15.0%) | NA |
Al-Tawfiq et al.68 | Saudi Arabia | 17 | 3 (17.6%) | 9 (52.9%) | NA |
Arabi et al.69 | Saudi Arabia | 330 | 142/252 (56.3%)e | 197/227 (86.8%)f | NA |
Al Ghamdi et al.70 | Saudi Arabia | 51 | 23 (45.1%) | 35 (68.6%) | NA |
